文献速递浆细胞疾病造血干细胞移植与细胞治疗

BCMA肽工程纳米颗粒增强抗原特异性CD8+细胞毒性T淋巴细胞诱导及抗多发性骨髓瘤功能:临床应用

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.
PubMed 文献 · Leukemia · 2019-08-19

研究开发BCMA特异性肽封装纳米颗粒,比较脂质体与PLGA纳米颗粒递送异源BCMA72-80肽至人树突状细胞的效果。PLGA纳米颗粒缓慢增加抗原呈递细胞肽摄取,诱导的BCMA特异性CTL对原代CD138+肿瘤细胞和MM细胞系具有更高抗肿瘤活性,伴Tetramer+/CD45RO+记忆CTL增加、CD28上调及中央记忆CTL维持更久。结果支持PLGA基BCMA免疫原性肽递送系统而非游离肽的治疗应用前景。

要点

  • PLGA纳米颗粒递送BCMA肽诱导的CTL抗MM活性高于脂质体纳米颗粒。
  • 增强的CTL功能伴记忆CTL表型改变和CD28上调。
  • 支持PLGA基BCMA纳米疫苗用于BCMA靶向免疫治疗。

核心结论

  • PLGA基BCMA免疫原性肽递送系统较游离肽能增强BCMA特异性CTL的诱导及多功Th1特异性抗MM活性。
  • PLGA纳米技术癌症疫苗具有增强BCMA靶向免疫治疗骨髓瘤的临床潜力。

研究设计与样本

  • 研究开发并表征BCMA特异性肽封装纳米颗粒制剂,比较脂质体与PLGA纳米颗粒递送异源BCMA72-80肽至人树突状细胞并诱导BCMA特异性CTL。

主要发现

  • 异源BCMA72-80肽封装脂质体或PLGA纳米颗粒显示均匀粒径分布并增加向人树突状细胞的肽递送,增强BCMA特异性CTL诱导。
  • 与脂质体纳米颗粒不同,PLGA纳米颗粒显示抗原呈递细胞肽摄取逐渐增加,诱导的BCMA特异性CTL对原代CD138+肿瘤细胞和MM细胞系具有更高抗肿瘤活性(CD107a脱颗粒、CTL增殖及IFN-γ/IL-2/TNF-α产生)。
  • 功能活性改善与Tetramer+/CD45RO+记忆CTL增加、Tetramer+CTL上CD28上调及中央记忆(CCR7+CD45RO+)CTL维持更久相关,同时抗MM活性最高且向效应记忆(CCR7-CD45RO+)CTL分化较少。

临床怎么用

  • 支持采用PLGA基BCMA免疫原性肽递送系统而非游离肽,以增强BCMA特异性CTL诱导及多功Th1特异性抗MM活性。
  • PLGA纳米技术癌症疫苗可用于增强BCMA靶向免疫治疗骨髓瘤的临床转化探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of these studies was to develop and characterize B-cell maturation antigen (BCMA)-specific peptide-encapsulated nanoparticle formulations to efficiently evoke BCMA-specific CD8+ cytotoxic T lymphocytes (CTL) with poly-functional immune activities against multiple myeloma (MM). Heteroclitic BCMA72-80 [YLMFLLRKI] peptide-encapsulated liposome or poly(lactic-co-glycolic acid) (PLGA) nanoparticles displayed uniform size distribution and increased peptide delivery to human dendritic cells, which enhanced induction of BCMA-specific CTL. Distinct from liposome-based nanoparticles, PLGA-based nanoparticles demonstrated a gradual increase in peptide uptake by antigen-presenting cells, and induced BCMA-specific CTL with higher anti-tumor activities (CD107a degranulation, CTL proliferation, and IFN-γ/IL-2/TNF-α production) against primary CD138+ tumor cells and MM cell lines. The improved functional activities were associated with increased Tetramer+/CD45RO+ memory CTL, CD28 upregulation on Tetramer+ CTL, and longer maintenance of central memory (CCR7+ CD45RO+) CTL, with the highest anti-MM activity and less differentiation into effector memory (CCR7- CD45RO+) CTL. These results provide the framework for therapeutic application of PLGA-based BCMA immunogenic peptide delivery system, rather than free peptide, to enhance the induction of BCMA-specific CTL with poly-functional Th1-specific anti-MM activities. These results demonstrate the potential clinical utility of PLGA nanotechnology-based cancer vaccine to enhance BCMA-targeted immunotherapy against myeloma.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bae J, Parayath N, Ma W, et al. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2019. PMID: 31427721. doi:10.1038/s41375-019-0540-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。